On September 13, 2018 ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, reported that members of its management team will present and host investor meetings at the following investor conferences in September 2018 (Press release, ERYtech Pharma, SEP 13, 2018, View Source;p=RssLanding&cat=news&id=2367187 [SID1234529508]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Morgan Stanley Global Healthcare Conference
Attendee: Gil Beyen, Chief Executive Officer
Location: New-York
Date / Presentation Time: September 13, 2018 at 4:40 PM EST
Webcast details: The presentation will be webcast live and can be accessed on Erytech’s Investor Relations website at View Source An archived version will be available within approximately two hours of the live presentation and can be accessed at the same location for 60 days.

BoursoCap/Investir Event
Attendee: Eric Soyer, Chief Financial Officer & Chief Operating Officer
Location : Groupe Les Echos – Le Parisien, Auditorium "10 Grenelle" Paris, France
Date / Presentation Time: September 18, 2018 at 06:00 PM CET

On September 12, 2018 Surefire Medical, Inc. (Surefire) reported the company is changing its name to TriSalus Life Sciences to better reflect the company’s contribution to patient care (Press release, Surefire Medical, SEPT 12, 2018, View Source [SID1234529409]). TriSalus is focused on developing drug delivery technology for use in solid tumors and improving the administration of immuno-oncology (IO) therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The re-naming of our company to TriSalus Life Sciences reflects an important step in our journey to build a leading oncology drug delivery company," said TriSalus CEO Mary Szela. "As researchers identify more ways to fight cancer, successful outcomes for patients are increasingly being defined by three strategic pillars for oncology treatment: the administration of the right therapeutic, the stimulation of the immune system, and equally important: a targeted delivery system to augment the therapeutic index."

TriSalus derives from the Roman goddess Salus, who represents health, prosperity, safety and welfare, while tri, represents the three strategic pillars of integrated cancer treatment. "The new name inspires our organization to make a meaningful difference for patients undergoing cancer treatment," added Szela.

The name change is one of many milestones supporting the transformation of the company. In 2018, the company:

Advanced its pipeline of drug delivery therapies with plans to launch its next-generation platform in 2019
Presented interim data from a national patient registry showing high tumor response rates among hepatocellular carcinoma patients treated with the company’s Pressure-Enabled Drug Delivery (PEDD) technology
Published a paper in the Journal of Vascular and Interventional Radiology indicating that further development of chimeric antigen receptor T cells (CAR-T) therapy should be done in combination with novel devices to allow for regional delivery of therapy into solid tumors
Closed a $5 million convertible note and initiated plans for Series E funding of $25 million to support investment in the company’s technology in combination with immuno-oncology therapy
About Pressure-enabled Drug Delivery (PEDD)

The high intratumoral pressure created by the tumor microenvironment limits the flow and accumulation of therapy in solid tumors. Pressure-Enabled Drug DeliveryTM (PEDD) can improve drug delivery to the tumor by creating a favorable pressure gradient that penetrates the hostile tumor microenvironment and increases drug concentration in the tumor without increasing systemic toxicity. Locoregional infusion with the company’s patented technology has been used in nearly 8,000 procedures worldwide for liver cancer and can be applied to a variety of other high-pressure solid tumors.

On September 12, 2018 Personalis, Inc., a leading provider of advanced genomic sequencing and analytics to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies, reported that they are scheduled to present at the 3rd Annual Rational Combinations 360o event in Philadelphia, PA on September 13, 2018 at 1:50 PM ET (Press release, Personalis, SEP 12, 2018, View Source [SID1234529427]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, entitled "Demystifying Tumor Immunogenomics: Key Challenges and Solutions," will discuss how the Personalis ACE ImmunoID Platform overcomes the limitations associated with conventional NGS approaches that are used in the preclinical and clinical development of new oncology therapeutics.

ACE ImmunoID is a universal immunogenomics platform, purpose-built for modern precision oncology applications, combining highly-sensitive exome and transcriptome sequencing with advanced analytics. The platform provides a multidimensional view of the tumor, its microenvironment, as well as its repertoire of tumor-specific neoantigens.

The Personalis presentation will be delivered by Erin N. Newburn, PhD, Associate Director, Field Applications Scientist.

On September 12, 2018 Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported that it will host a conference call on September 13, 2018 at 10 am EDT to discuss preliminary results from its Phase 1 dose-escalation study of its proprietary topical Endoxifen in male subjects (Press release, Atossa Genetics, SEP 12, 2018, http://ir.atossagenetics.com/news/detail/863/atossa-genetics-to-host-conference-call-to-announce-preliminary-results-from-male-phase-1-study-of-topical-endoxifen-thursday-september-13-2018-at-10-am-edt [SID1234530342]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1 study was a double-blind, placebo-controlled, repeat dose study of 24 healthy male subjects. Atossa assessed safety, tolerability and the pharmacokinetics of proprietary formulations of topical Endoxifen at varying dose levels over 28 days. The study was conducted on behalf of Atossa by CPR Pharma Services Pty Ltd., Thebarton, SA, Australia.

Due to expected high call attendance, participants are asked to preregister for the call through the following link: View Source Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without internet access or who are unable to pre-register may dial in by calling: 1-844-824-3830 (domestic), 1-412-317-5140 (international) and Canada Toll Free: 1-855-669-9657. Callers should ask to be joined into the Atossa Genetics call.

The conference call will also be available through a live webcast at View Source which is also available at www.atossagenetics.com on the Company’s IR events page at View Source

Management will answer pre-submitted questions gathered prior to the conference call in the Question and Answer period of the call. Interested parties may submit questions for management’s consideration prior to the call by submitting them in writing to Atossa Genetics’ Investor Relations at [email protected].

A replay of the call will be available approximately one hour after the end of the call through October 13, 2018. The replay can be accessed via Atossa’s website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay access code is 10124008.

On September 12, 2018 Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, reported that it will host a conference call and webcast to discuss its exclusive regional license and collaboration agreement with Novocure for Tumor Treating Fields on Thursday, September 13, 2018 at 8:30 a.m. EDT (Press release, Zai Laboratory, SEP 12, 2018, View Source;p=RssLanding&cat=news&id=2367153 [SID1234530329]). On the call, Zai Lab’s senior management team will provide an overview of the transaction.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Conference Call Details
Date: Thursday, September 13th, 2018
Time: 8:30 a.m. EDT
Dial-In Details: 1-866-394-4355 (US); 1-314-888-4344 (International); 4006828609 (China)
Conference ID: 9295709

A live webcast and replay will be available on the Investor section of Zai Lab’s website at View Source A slide presentation will accompany the webcast and will also be available on the Company’s website.